801 results about "Hepatic Cancers" patented technology

The invention describes a health product additive and preparation for sots or hepatitis B pathogen carriers By adding medicinal fungus fermentation liquor as additive and using effective components and fine powder extracted from plants and herbal medicines by solvent as adjuvant, the health product can be made into forms of effervescent tablet, buccal tablet, chewable tablet, oral taken tablet, candy, chocolate, chewing gum, oral liquid, particle, soluble granules, capsule, aerosol, liquid beverage and solid beverage. The product can relieve alcohol effect, nourish stomach, protect liver, and help to remit hepatitis B virus and hepatitis liver cancer patient condition, achieves a quite important effect for protecting the health of the sots or hepatitis B pathogen carriers in daily or social occasions. The invention provides a good idea to the utilization of the large amount of active fermentation liquid generated with the thallus pharmacy in the medicinal fungus fermentation industries, and also provides a effective approach for increasing the utilization value of the large amount of wild plant resources such as wild jujube and haw widely distributed in the north areas.

ADAMTS-7 expression and activity are up regulated in patients that have cancers of epithelial origin. Accordingly, the present invention is directed to methods diagnosis of cancers of epithelial origin (e.g. breast cancer, prostate cancer, bladder cancer, brain cancer and hepatic cancer). In particular, the presence of ADAMTS-7 in a biological sample is indicative of cancer of epithelial origin. Thus, measuring the level of ADAMTS-7 in biological samples (e.g. urine or blood) provides a quick, easy, and safe screen that can be used to diagnose cancer in a patient.

The invention discloses a traditional Chinese medicine preparation for treating cancer, which is prepared by 103 types of bulk drugs such as solidago decurrens, Chinese sage herb, hypericum japonicumand the like. A preparation method of the traditional Chinese medicine preparation comprises the following steps: preparing the bulk drugs into water extract by a conventional method; using the prepared water extract for preparing oral solution by a traditional method; drying the obtained water extraction, then conducting grinding and sieving; taking the throughs for extracting powder, and using the extracted powder for preparing tablets, granules, electuaries or capsules by a traditional method. The preparation method also can be as follows: sieving out the dust of the bulk drugs, conductinggrinding and sieving, taking the throughs, conducting disinfection and sterilization to obtain raw powder, and using the raw powder for preparing tablets, granules, electuaries or capsules by a traditional method. With drugs mixed rationally, the traditional Chinese medicine preparation addresses both the symptoms and root causes of cancer. The bulk drugs are frequently-used common Chinese drugs,have low preparation cost and small side effect, and can effectively enhance own immunity, attack pathogen while do not damage body. The traditional Chinese medicine preparation can cure various typesof cancer, particularly lung cancer, stomach cancer, liver cancer, esophageal cancer, pancreatic cancer, cervical cancer and breast cancer.

The present invention relates to a novel compound and its uses, which is an extract isolated and purified from Antrodia camphorate, in particular to 4-hydroxy-2,3 -dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone, and its use in tumor growth inhibition. The compound of the invention, which has never been discovered in Antrodia camphorate, can be applied in inhibiting the growth of cancer cells, such as breast cancer, hepatic cancer and prostate cancer; and be used as a pharmaceutical composition to inhibit the tumor growth; or further be applied in prevention of heart and blood vessel disease or dietary supplements for health needs through its antioxidant activity.

The present application describes a method of treating prostate cancer, melanoma or hepatic cancer in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of the heterocyclic compound represented by Formula I or its pharmaceutically acceptable salt:

The invention relates to a novel liver target drug carrier-glycyrrhetinic acid-polyethylene glycol / chitosan or chitosan derivative liver target compound drug delivery system. During the preparation of the nano-drug delivery system, the liver target small-molecule glycyrrhetinic acid is firstly used for modifying amino polyethylene glycol by the different sites, then a water soluble big-molecule liver target compound is prepared and is mixed with a solution containing chitosan or chitosan derivative by a certain proportion, an ion cross-linking agent is added under the stirring condition, and a target group is introduced at the same time of the spontaneous formation of nanoparticles by physical winding and electrostatic interaction. The method of introducing the target group of the invention is novel, the formation of spheres is simple, the conditions are moderate, and the content of the target group is high (the weight percentage of glycyrrhetinic acid is 5 to 30 percent). The drug delivery system has strong killing capacity to the cancer cells, the in vitro experiments show that the drug delivery system has very strong binding capacity with the liver cells, and the high content of the target group can improve the liver target capacity of the drug delivery system, realize the target positioning of the liver and open a new way for the treatment of liver cancer.

PCT No. PCT / US97 / 11564 Sec. 371 Date Apr. 14, 1999 Sec. 102(e) Date Apr. 14, 1999 PCT Filed Jul. 8, 1997 PCT Pub. No. WO98 / 01132 PCT Pub. Date Jan. 15, 1998The present invention relates to specific adamantyl or adamantyl group derivative containing retinoid compounds induce apoptosis of cancer cells. These adamantyl retinoid derivatives are useful for the treatment of many cancers and solid tumors, especially androgen-independent prostate cancer, skin cancer, pancreatic carcinomas, colon cancer, melanoma, ovarian cancer, liver cancer, small cell lung carcinoma, non-small cell lung carcinoma, cervical carcinoma, brain cancer, bladder cancer, breast cancer, neuroblastoma / glioblastoma, and leukemia. Also, the invention relates to novel adamantyl or adamantyl group derivative compounds which are useful as active agents for the treatment or prevention of keratinization disorders and other dermatological conditions, and other diseases.

The invention provides a method of determining an HCC subtype in a subject comprising a) obtaining a sample from the subject, b) assaying the sample to detect the expression of 1 or more biomarkers, and c) correlating the expression of the biomarkers with an HCC subtype in a subject. The invention further provides methods of detecting HCC stem cells in a sample. Additionally, the invention provides methods and compositions for treating subjects with HCC that take advantage of the biomarkers associated with HCC stem cells.

The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and / or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis / cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery.

The invention discloses a method for preparing a meso-porous silicon nano medicine carrier with cell specificity target, reduction responsiveness and triple anticancer treatment effects. The method comprises the following steps: firstly, synthesizing meso-porous silicon nano particles by using a gel dissolution method, subsequently, introducing a disulfide bond onto the surface of a meso-porous silicon nano reservoir by using a chemical modification method, innovatively fixing cytochrome C with an apoptosis-inducing function onto the surface of the meso-porous silicon nano reservoir, blocking meso-porous channels with medicines, finally modifying DNA (Deoxyribose Nucleic Acid) aptamer single chain molecules (AS1411, with a cancer cell apoptosis-inducing function) onto the surface of a meso-porous silicon / cytochrome C nano composite system, and taking the system as specificity ligand of a receptor (nucleolin protein) which is overexpressed on the surface of liver cancer cytomembrane, thereby establishing a multifunctional composite type nano medicine carrier system for achieving triple anticancer treatment under combined action of medicines, blocking substances and target molecules inside meso-pores.

The present invention relates to a class of pyridazinones of formula I, which comprises 6-[3-(trifluoromethyl)phenyl]pyridazin-3(2H)-one as a mother nucleus, the preparation method thereof and the use thereof in manufacturing medicaments against tumors, especially liver cancer.

The invention discloses a cancer pain-relieving plaster prepared by a preparation A and a preparation B, wherein the preparation A is prepared by five branches, five skins, one brick, one stone, five cores, and the like; the preparation B is prepared by poria cocos, pinellia ternate, jackinthepulpit tuber rhizome, trichosanthes kirilowii maxim, centipede, zaocys dhumnade, and the like. When the cancer pain-relieving plaster is prepared, the preparation B is added into the preparation A to be decocted for 4.5-5.5 hours, red lead is added to be mixed to pasty fluid, then cold water is added for steeping to releasing fire-toxin, water is changed once one day, and the plaster is obtained after steeping for 7 days. When the plaster is used, the plaster is coated on cotton cloth or plaster paster. The cancer pain-relieving plaster mainly aims at tumour cancers of lung cancer, gastric cancer, liver cancer, pancreatic cancer, colon caner, rectal caner, kidney cancer, bladder caner, breast cancer, cervical cancer, ovarian cancer, esophagus cancer, laryngeal cancer, and the like and is obvious in pain-relieving effect.

The invention discloses a traditional Chinese patent medicine with the components of plant polysaccharide and bamboo extract for treating medium and terminal cancer, which has a formula as follow: 10 kg of whangee, 5 kg of CV.Ventricousinternode, 10 kg of moso bamboo, 5 kg of palm bamboo, 5 kg of phyllostachys glauca, 10 kg of fishscale bamboo and 5 kg of fortune paulownia bark. A method for preparing the traditional Chinese patent medicine comprises the following steps: adding 50 kg of water into the total 50 kg of the medical materials; decocting the mixture to obtain 200 ml to 400ml of concentrated material; adding mineral trace elements: 0.01 milligrams of calcium, 0.01 milligrams of ferrum, 0.01 milligrams of zinc, 0.01 milligrams of selenium, 0.01 milligrams of iodine and 0.01 milligrams of potassium which are essential to the body into the concentrated material after removing impurities and filtering; finally, fermenting the final mixture to obtain the medicine, and bottling the medicine for use. The traditional Chinese patent medicine has the beneficial effects of treating medium and terminal esophagus cancer, gastric cancer, intestinal cancer, liver cancer, cerebral cancer and other cancers and treating gastritis, gastric ulcer, hepatitis, rhinitis and other inflammation. In addition, the traditional Chinese patent medicine can be also used for treating skin cancer and various kinds of skin diseases by exterior spreading. The traditional Chinese patent medicine takes effect rapidly and has no toxic and side effect.

The invention relates to a sodium alginate micro ball vessel suppository which contains soluble medicine, and relative preparation and application, wherein said agent can be divided into two kinds as wet ball and dry ball made from degradable biological material; said carrier comprises sodium alginate, blood serum albumin, chitose, or transparent sodium solution, via the static to be solidified with calcium ion, to be made into the micro ball at 20 mum-1000 mum. The inventive material has high mechanical strength, biological compatibility, biological degradability and stability. The invention can be used to cure the vessel suppository of variable cancers.

A water soluble extract from a plant of Solanum genus consists essentially of at least 60%–90% of solamargine and solasonine. A process for preparing the water soluble extract from the plant of Solanum genus involves the steps of hydrolysis with an acid, precipitation with a base, and separation treatments using chloroform, alcohol and water as extraction solvents. The water soluble extract prepared from the process can be directly dissolved in pure or neutral pH water to form a yellowish clear and transparent aqueous solution having a water solubility ranging from 2˜20 mg / ml or higher.The water soluble extract can be used as an active component in a pharmaceutical composition for inhibiting the growth of tumor / cancer cells, in particular liver cancer cells, lung cancer cells and breast cancer cells.

The invention discloses a class of anti-tumor compounds containing a triazole heterocyclic structure and an application thereof, belonging to the technical field of medicinal chemistry. The compounds containing the triazole heterocyclic structure introduce quintuple 1,2,3-triazole ring in the form of side chains through the amino condensation, bromination, nitrine substitution, link reaction and other reactions on the basis of naphthalimide parent structure, select tetrazolium salt reduction to test 7721 hepatocellular in the experiment of inhibiting proliferation of tumor cells, and also select sulfonyl rhodamine B protein staining method to test MCF-7 breast cancer cells. The experiment results show that the anti-tumor compounds have wide anti-tumor activity and good inhibition effect on the normal growth of tumor cells derived from different tissues of liver cancer, breast cancer and the like.

The nanoparticles composed of γ-PGA-PLA block copolymers that are conjugated with galactosamine as a potential drug delivery system and loaded with anticancer drugs for treating liver cancers.

The invention discloses a new use of phenanthridine biologic alcali of general formula I containing coumarone and its derivant in preparing anti-hepatitis b virus medicament.The biologic alcali has tumor cell apoptosis inducing effect, has strong inhibiting activity against to such pathogen, has antiviral effect, and is expected for treating liver cancer, wherein R1 to R10, R12 and R13 is hydrogen, hydroxy, carbon chain or naphthenic base with 1-12 carbon atoms, alkoxyl or acyloxy group, benzyloxy, chlorine and other halogen atoms, amino group, methylol, aldehyde group, carbonyl, acetonyl, carboxy, sulacyloxy, 4-methyl-benzenesulfonyloxyl, arylsulfonyloxy, diphenylphosphonoxyl and -OCONH2; R11 is hydrogen, methyl or oxygen atom; R14 and R15 are respectively hydrogen or methyl.

The invention relates to the medicine technical field, in particular to saponin compounds of Siraitic acid IIB and Siraitic acid IIC which are extracted and separated from fructus momordicae roots, a method for preparing the same and application thereof in an anti-tumor medicine. The molecular formulas of the two compounds are C40H60O14 and C41H62O15 respectively. By various modern spectral analysis, particularly the application of advanced two-dimensional nuclear magnetic resonance spectrum to comprehensive analysis, the chemical structures of the two compounds are determined. In vitro anti-tumor tests show that the compound Siraitic acid IIB can obviously inhibit lung cancer cells A-549 and liver cancer cells Hep-G2, and the compound Siraitic acid IIC can also obviously inhibit liver cancer cells Hep-G2. The invention provides lead compound for research on a new anti-tumor medicine, and has essential values in comprehensively developing and utilizing fructus momordicae resources.

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

The present invention provides preparation process of antrodia camphorata polysaccharide and antrodia camphorata triterpene with adsorptive microporous resin and its product, and relates to chromatographic separation technology with adsorptive microporous resin and extraction of effective Chinese medicine component. Antrodia camphorata sporophore or mycelium is extracted with hot water and sectional eluted in microporous resin with water and alcohol to obtain antrodia camphorata polysaccharide and antrodia camphorata triterpene separately. The products of the present invention are used in preparing medicine and antrodia camphorata triterpene has excellent liver cancer cell resisting activity.

The invention relates to a composite developing thermosensitive gel embolizing agent as well as a preparation method and application thereof. The preparation method comprises the following steps: firstly, preparing a mixed aqueous solution of an anticancer active substance, a thermosensitive material and a developing agent into composite developing thermosensitive gel; secondly, forming a composite developing thermosensitive gel embolizing agent by the composite developing thermosensitive gel and a coagulant on the scene, wherein the thermosensitive material is hydroxyl C1-4 alkyl cellulose, Pluronic, alginate or a mixture of the substances; the anticancer active substance is arsenic trioxide, docetaxel, cisplatin, carboplatin, nedaplatin, oxaliplatin, lobaplatin, miriplatin, siRNA or a mixture of the substances; the developing agent is a water-soluble developing agent of iodixanol, ioversol or iohexol and the like. The preparation method disclosed by the invention is simple and convenient, is suitable for industrial large-scale production, is particularly suitable for preparing an embolizing agent which is biodegradable and good in biocompatibility and is used for hemorrhagic diseases, and is especially suitable for preparing the composite developing thermosensitive gel embolizing agent for treating liver cancer, kidney cancer, lung cancer, prostate cancer, uterine myoma or splenic tumor and the like.

The invention discloses a high- purity of osthol, structure proof with spectral analysis, method for preparation, stability study, acute toxicity study, the drug compositions containing osthol, and new drug utilities of the natural product. By the technique steps of extracted Chinese pharmacy conidium fruit with alcohol, decolorizing and enriching by large-hole adsorption resin, and separating and purifying, it can prepare osthol with a purity of above 98%. The study expresses that the osthol has a clear utility of anti-cancer, anti-auto lymphoma, and so on.

The invention relates to novel anti-tumor application of an alkaloid compound penicillium enol B1 from penicillium citrinum. The penicillium citrinum IBPT-5 is collected in the China Center for Type Culture Collection (CCTCC), which is located in Wuhan University and has the collection number of CCTCC NO:M2013713, on December 25, 2013. The compound has good anti-tumor activity to various tumor cells, and can be used for preparing cell proliferation inhibition medicines or anti-tumor medicines for anti-tumor study, wherein tumor cells comprise human colon cancer cells SW620, human hepatoma cells Huh7, human gastric carcinoma cells SGC-7901, human gastric carcinoma cells BGC-823, human colon cancer cells SW480, human esophageal cancer cells EC9706, human highly metastatic lung carcinoma cells 95-D, human hepatoma cells PLC, human gastric carcinoma cells HGC-27 and human lymphoma cells RAJI.

This invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations (e.g., in oncogenes and tumor suppressor genes) that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both, preferably by inducible, reversible, and / or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene, and by transplanting the resulting hepatocytes into a recipient non-human animal. The invention further provides a method to treat cancer involving cooperative interactions between a tumor cell senescence program and the innate immune system.

The invention discloses Chinese medicinal powder for treating liver cancer, lung cancer and pancreatic cancer. The Chinese medicinal powder comprises the following raw materials by weight: 14 to 16g of root of red-rooted salvia, 7 to 9g of lightyellow sophora root, 9 to 11g of largehead atractylodes rhizome, 14 to 16g of common leafflower herb, 8 to 9g of Chinese sage herb, 9 to 11g of mahonia fortunei, 9 to 11g of glabrous greenbrier rhizome, 9 to 11g of heartleaf houttuynia herb, 9 to 11g of buttercup root, 9 to 11g of herba geranii, 9 to 11g of stringy stonecrop herb, 19 to 21g of buckwheat, 7 to 9g of hairyvein agrimonia herb and bud, 9 to 11g of oriental waterplantain rhizome, 15g of bupleurum, 9 to 11g of mongolian snakegourd root, 9 to 11g of akebia trifoliata koidz, 14 to 16g of motherwort herb, 19 to 21g of giant knotweed rhizome, 8g of rhodiola, 9 to 11g of amur corktree bark, 38 to 42g of astragalus, 9 to 11g of baical skullcap root, 14 to 16g of rhubarb, 9 to 11g of lily, 9 to 11g of bittersweet herb, 14 to 16g of Chinese lobelia herb, 14 to 16g of barbed skullcap herb, 14 to 16g of spreading hedyotis herb, 7 to 9g of pinellia tuber, 9 to 11g of paris polyphylla, 9 to 11g of gardenia, 9 to 11g of agaric, 14 to 16g of snow of june herb, 19 to 21g of Chinese brake herb, 9 to 11g of India madder root, 9 to 11g of clematis root, 9 to 11g of gentian, 9 to 11g of Japanese climbing fern spore, 9 to 11g of Chinese pyrola herb, 9 to 11g of sinkiang arnebia root, 9 to 11g of paniculate swallowwort root, 9 to 11g of costustoot, 9 to 11g of zanthoxylum bungeanum maxim, 9 to 11g of radix stephaniae tetrandrae, 30g of glossy privet fruit, 19 to 21g of dendrobium, 14 to 16g of sweet wormwood herb, 19 to 21g of chinaroot greenbrier and 9 to 11g of zedoary. The Chinese medicinal powder has the advantages of readily available raw materials, good effect of treating cancers, quick response and high cure rate.